<p>Zymeworks Inc.（纽约证券交易所代码：ZYME - 获取免费报告）在周四上涨了 5.4%。该股交易最高价为 23.98 美元，最后交易价为 23.8270 美元。在交易过程中，共成交了 1,059,781 股，较平均交易量 663,603 股增加了 60%。该股此前收盘价为 22.60 美元。</p>
<h2>分析师评级调整</h2>
<ul>
<li>Zymeworks 为不仅仅是长期投资者提供了希望</li>
</ul>
<p>多位分析师对 ZYME 股票发布了报告。花旗集团将 Zymeworks 的目标价从 19.00 美元上调至 22.00 美元，并在 8 月 11 日的研究报告中给予该股 “买入” 评级。B. Riley 在 10 月 10 日的研究报告中开始覆盖 Zymeworks 的股票，给予 “买入” 评级和 30.00 美元的目标价。HC Wainwright 在周二将 Zymeworks 的目标价从 26.00 美元上调至 32.00 美元，并给予公司 “买入” 评级。Stifel Nicolaus 在周三将 Zymeworks 的目标价从 30.00 美元上调至 40.00 美元，并给予该股 “买入” 评级。最后，Leerink Partners 在周一为 Zymeworks 设定了 37.00 美元的目标价。八位分析师对该股给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Zymeworks 的平均评级为 “适度买入”，共识目标价为 29.88 美元。</p>
<p><strong>获取我们关于 Zymeworks 的最新研究报告</strong></p>
<h2>Zymeworks 股票上涨 5.4%</h2>
<p>该公司的 50 日简单移动平均线为 17.87 美元，200 日简单移动平均线为 14.71 美元。该公司的市值为 17.8 亿美元，市盈率为-15.88，贝塔值为 1.48。</p>
<p>Zymeworks（纽约证券交易所代码：ZYME - 获取免费报告）最近一次发布财报是在 11 月 6 日，报告显示该季度每股收益为（0.26 美元），超出市场共识预期的（0.28 美元）0.02 美元。Zymeworks 的净利润率为-182.75%，股本回报率为-23.00%。该季度的营业收入为 2761 万美元，而分析师预期为 3369 万美元。去年同期，该公司的每股收益为（0.39 美元）。该公司的季度收入同比增长 72.6%。整体来看，卖方分析师预计 Zymeworks Inc.在本财年将发布-1.39 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>多家机构投资者最近对该公司的持仓进行了调整。EcoR1 Capital LLC 在第二季度将其在 Zymeworks 的持仓增加了 33.1%。EcoR1 Capital LLC 目前拥有 22970388 股该公司的股票，价值 288278000 美元，此前在上个季度增持了 5710840 股。Rubric Capital Management LP 在第二季度将其在 Zymeworks 的持仓增加了 8.6%。Rubric Capital Management LP 目前拥有 4710551 股该公司的股票，价值 59117000 美元，此前在上个季度增持了 372107 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Zymeworks 的持仓增加了 184.2%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 目前拥有 3879945 股该公司的股票，价值 46210000 美元，此前在上个季度增持了 2514834 股。Vestal Point Capital LP 在第三季度将其在 Zymeworks 的持仓增加了 53.5%。Vestal Point Capital LP 目前拥有 1765000 股该公司的股票，价值 30146000 美元，此前在上个季度增持了 615000 股。最后，德意志银行在第一季度将其在 Zymeworks 的持仓增加了 0.4%。德意志银行目前拥有 1552612 股该公司的股票，价值 18492000 美元，此前在上个季度增持了 5840 股。92.89% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Zymeworks</h2>
<p>（获取免费报告）</p>
<p>Zymeworks Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于癌症治疗的生物治疗药物。该公司的主要产品候选包括 zanidatamab，一种人类表皮生长因子受体 2（HER2），目前正在进行 1 期、2 期和 3 期临床试验，包括某些正在进行的关键临床试验；以及 zanidatamab zovodotin，一种针对 HER2 的抗体药物偶联物，目前正在进行 2 期临床试验，旨在治疗晚期或转移性 HER2 表达肿瘤。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票超过 Zymeworks</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂？</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年</li>
<li>万亿市场市值的意义超越了数字本身</li>
<li>Joby 和 Archer 在阿联酋开创了新的战略篇章</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Zymeworks 吗？</h2>
<p>在考虑 Zymeworks 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Zymeworks 并不在名单上。</p>
<p>虽然 Zymeworks 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ZYME

<p>Zymeworks Inc.（纽约证券交易所代码：ZYME）股票上涨 5.4%，至 23.8270 美元，交易量增加 60%。分析师们对 ZYME 股票进行了升级，花旗集团、B. Riley、HC Wainwright、Stifel Nicolaus 和 Leerink Partners 均给予 “买入” 评级并提高了目标价格。Zymeworks 报告第三季度每股收益为（0.26 美元），超出预期，收入同比增长 72.6%。机构投资者增加了在 Zymeworks 的持仓。该公司开发用于癌症治疗的生物治疗药物</p>

<p>Zymeworks Inc. (NYSE:ZYME - Get Free Report) shot up 5.4% on Thursday . The stock traded as high as $23.98 and last traded at $23.8270. 1,059,781 shares traded hands during trading, an increase of 60% from the average session volume of 663,603 shares. The stock had previously closed at $22.60.</p>
<div class="lb-trans"><p>Zymeworks Inc.（纽约证券交易所代码：ZYME - 获取免费报告）在周四上涨了 5.4%。该股交易最高价为 23.98 美元，最后交易价为 23.8270 美元。在交易过程中，共成交了 1,059,781 股，较平均交易量 663,603 股增加了 60%。该股此前收盘价为 22.60 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 为不仅仅是长期投资者提供了希望</li>
</ul>
</div><p>A number of analysts have issued reports on ZYME shares. Citigroup raised their price target on Zymeworks from $19.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, August 11th. B. Riley began coverage on shares of Zymeworks in a research report on Friday, October 10th. They issued a &#34;buy&#34; rating and a $30.00 target price on the stock. HC Wainwright boosted their target price on shares of Zymeworks from $26.00 to $32.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Stifel Nicolaus increased their price target on shares of Zymeworks from $30.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday. Finally, Leerink Partners set a $37.00 price target on shares of Zymeworks in a report on Monday. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Zymeworks has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $29.88.</p>
<div class="lb-trans"><p>多位分析师对 ZYME 股票发布了报告。花旗集团将 Zymeworks 的目标价从 19.00 美元上调至 22.00 美元，并在 8 月 11 日的研究报告中给予该股 “买入” 评级。B. Riley 在 10 月 10 日的研究报告中开始覆盖 Zymeworks 的股票，给予 “买入” 评级和 30.00 美元的目标价。HC Wainwright 在周二将 Zymeworks 的目标价从 26.00 美元上调至 32.00 美元，并给予公司 “买入” 评级。Stifel Nicolaus 在周三将 Zymeworks 的目标价从 30.00 美元上调至 40.00 美元，并给予该股 “买入” 评级。最后，Leerink Partners 在周一为 Zymeworks 设定了 37.00 美元的目标价。八位分析师对该股给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Zymeworks 的平均评级为 “适度买入”，共识目标价为 29.88 美元。</p>
</div><p><strong>Get Our Latest Research Report on Zymeworks</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Zymeworks 的最新研究报告</strong></p>
</div><h2>Zymeworks Stock Up 5.4%</h2>
<div class="lb-trans"><h2>Zymeworks 股票上涨 5.4%</h2>
</div><p>The firm's 50 day simple moving average is $17.87 and its 200-day simple moving average is $14.71. The company has a market capitalization of $1.78 billion, a PE ratio of -15.88 and a beta of 1.48.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 17.87 美元，200 日简单移动平均线为 14.71 美元。该公司的市值为 17.8 亿美元，市盈率为-15.88，贝塔值为 1.48。</p>
</div><p>Zymeworks (NYSE:ZYME - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $27.61 million for the quarter, compared to analyst estimates of $33.69 million. During the same quarter in the previous year, the business posted ($0.39) EPS. The business's quarterly revenue was up 72.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Zymeworks Inc. will post -1.39 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Zymeworks（纽约证券交易所代码：ZYME - 获取免费报告）最近一次发布财报是在 11 月 6 日，报告显示该季度每股收益为（0.26 美元），超出市场共识预期的（0.28 美元）0.02 美元。Zymeworks 的净利润率为-182.75%，股本回报率为-23.00%。该季度的营业收入为 2761 万美元，而分析师预期为 3369 万美元。去年同期，该公司的每股收益为（0.39 美元）。该公司的季度收入同比增长 72.6%。整体来看，卖方分析师预计 Zymeworks Inc.在本财年将发布-1.39 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the company. EcoR1 Capital LLC increased its position in shares of Zymeworks by 33.1% during the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company's stock worth $288,278,000 after acquiring an additional 5,710,840 shares during the last quarter. Rubric Capital Management LP raised its position in shares of Zymeworks by 8.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company's stock valued at $59,117,000 after purchasing an additional 372,107 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Zymeworks by 184.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company's stock valued at $46,210,000 after buying an additional 2,514,834 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Zymeworks by 53.5% during the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company's stock valued at $30,146,000 after buying an additional 615,000 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Zymeworks by 0.4% during the first quarter. Deutsche Bank AG now owns 1,552,612 shares of the company's stock worth $18,492,000 after buying an additional 5,840 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家机构投资者最近对该公司的持仓进行了调整。EcoR1 Capital LLC 在第二季度将其在 Zymeworks 的持仓增加了 33.1%。EcoR1 Capital LLC 目前拥有 22970388 股该公司的股票，价值 288278000 美元，此前在上个季度增持了 5710840 股。Rubric Capital Management LP 在第二季度将其在 Zymeworks 的持仓增加了 8.6%。Rubric Capital Management LP 目前拥有 4710551 股该公司的股票，价值 59117000 美元，此前在上个季度增持了 372107 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度将其在 Zymeworks 的持仓增加了 184.2%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 目前拥有 3879945 股该公司的股票，价值 46210000 美元，此前在上个季度增持了 2514834 股。Vestal Point Capital LP 在第三季度将其在 Zymeworks 的持仓增加了 53.5%。Vestal Point Capital LP 目前拥有 1765000 股该公司的股票，价值 30146000 美元，此前在上个季度增持了 615000 股。最后，德意志银行在第一季度将其在 Zymeworks 的持仓增加了 0.4%。德意志银行目前拥有 1552612 股该公司的股票，价值 18492000 美元，此前在上个季度增持了 5840 股。92.89% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Zymeworks</h2>
<div class="lb-trans"><h2>关于 Zymeworks</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.</p>
<div class="lb-trans"><p>Zymeworks Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于癌症治疗的生物治疗药物。该公司的主要产品候选包括 zanidatamab，一种人类表皮生长因子受体 2（HER2），目前正在进行 1 期、2 期和 3 期临床试验，包括某些正在进行的关键临床试验；以及 zanidatamab zovodotin，一种针对 HER2 的抗体药物偶联物，目前正在进行 2 期临床试验，旨在治疗晚期或转移性 HER2 表达肿瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Zymeworks</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Joby and Archer Forge a New Strategic Chapter in the UAE</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Zymeworks</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂？</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年</li>
<li>万亿市场市值的意义超越了数字本身</li>
<li>Joby 和 Archer 在阿联酋开创了新的战略篇章</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Zymeworks Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Zymeworks 吗？</h2>
</div><p>Before you consider Zymeworks, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Zymeworks 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Zymeworks 并不在名单上。</p>
</div><p>While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zymeworks 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Zymeworks（NYSE:ZYME）股价上涨 5.4% - 这是怎么回事